Go Pro
→ Three oil giants buried the same discovery for 50 years (From Behind the Markets) (Ad)tc pixel Free BCLI Stock Alerts

Brainstorm Cell Therapeutics (BCLI) Financials

Brainstorm Cell Therapeutics logo
$0.96 -0.04 (-4.00%)
As of 07/24/2026 03:56 PM Eastern
Compare
Annual Income Statements for Brainstorm Cell Therapeutics

Annual Income Statements for Brainstorm Cell Therapeutics

This table shows Brainstorm Cell Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -8.49 -4.98 -4.95 -14 -23 -32 -24 -24 -17 -12 -10
Consolidated Net Income / (Loss)		 -8.49 -4.98 -4.95 -14 -23 -32 -24 -24 -17 -12 -10
Net Income / (Loss) Continuing Operations		 -8.54 -5.08 -5.00 -14 -23 -32 -24 -24 -17 -12 -10
Total Pre-Tax Income 		-8.54 -5.08 -5.00 -14 -23 -32 -24 -24 -17 -12 -10
Total Operating Income		 -8.54 -5.08 -5.00 -14 -23 -32 -25 -25 -21 -12 -9.95
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 8.49 5.08 5.00 14 23 32 25 25 21 12 9.95
Selling, General & Admin Expense		 3.59 2.83 4.02 5.77 5.80 9.36 9.30 11 11 7.04 5.78
Research & Development Expense		 4.95 2.25 0.98 8.29 17 22 15 14 11 4.65 4.18
Total Other Income / (Expense), net		 0.00 0.00 0.00 0.00 0.00 -0.13 0.08 0.55 4.69 0.07 -0.35
Interest & Investment Income		 - - - - - - 0.08 - - -0.08 -0.53
Other Income / (Expense), net		 - - - - - - - 0.00 4.69 0.15 0.18
Basic Earnings per Share		 ($0.46) - - ($0.70) ($1.06) ($1.07) ($0.68) ($0.66) ($6.00) ($2.31) ($1.11)
Weighted Average Basic Shares Outstanding		 18.41M 18.66M 18.78M 20.00M 21.91M 29.85M 36.18M 36.51M 2.87M 5.02M 9.27M
Diluted Earnings per Share		 ($0.46) - - ($0.70) ($1.06) ($1.07) ($0.68) ($0.66) ($6.00) ($2.31) ($1.11)
Weighted Average Diluted Shares Outstanding		 18.41M 18.66M 18.78M 20.00M 21.91M 29.85M 36.18M 36.51M 2.87M 5.02M 9.27M
Weighted Average Basic & Diluted Shares Outstanding		 18.41M 18.66M 18.78M 20.00M 21.91M 29.85M 36.49M 36.68M 68.34M 6.52M 11.03M

Quarterly Income Statements for Brainstorm Cell Therapeutics

This table shows Brainstorm Cell Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.23 -5.58 -3.40 -2.54 -2.71 -2.97 -2.86 -2.90 -2.11 -2.43 -2.13
Consolidated Net Income / (Loss)		 -6.04 -0.77 -3.40 -3.36 -2.71 -2.15 -2.86 -2.90 -2.11 -2.43 -2.13
Net Income / (Loss) Continuing Operations		 -6.04 -0.32 -3.40 -3.36 -2.71 -2.15 -2.86 -2.90 -2.11 -2.39 -2.13
Total Pre-Tax Income 		-6.04 -0.32 -3.40 -3.36 -2.71 -2.15 -2.86 -2.90 -2.11 -2.39 -2.13
Total Operating Income		 -6.04 -4.80 -2.47 -2.98 -3.05 -3.19 -3.09 -2.57 -2.05 -2.24 -2.05
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 6.04 4.80 2.47 2.98 3.05 3.19 3.09 2.57 2.05 2.24 2.05
Selling, General & Admin Expense		 2.71 3.11 1.51 2.06 2.00 1.47 1.79 1.45 1.15 1.39 1.28
Research & Development Expense		 3.33 1.70 0.96 0.92 1.05 1.72 1.30 1.12 0.90 0.85 0.76
Total Other Income / (Expense), net		 0.00 4.48 -0.93 -0.38 0.34 1.04 0.23 -0.33 -0.06 -0.14 -0.08
Interest & Investment Income		 - - 0.01 0.03 -0.05 -0.07 0.05 -0.33 -0.06 - -0.08
Other Income / (Expense), net		 0.00 4.69 -0.94 -0.41 0.39 1.10 0.18 0.00 0.00 - 0.00
Basic Earnings per Share		 ($0.45) ($1.94) ($0.75) ($0.60) ($0.51) ($0.45) ($0.45) ($0.34) ($0.19) ($0.13) ($0.19)
Weighted Average Basic Shares Outstanding		 2.95M 2.87M 4.32M 4.75M 5.31M 5.02M 6.34M 8.62M 11.01M 9.27M 11.03M
Diluted Earnings per Share		 ($0.45) ($1.94) ($0.75) ($0.60) ($0.51) ($0.45) ($0.45) ($0.34) ($0.19) ($0.13) ($0.19)
Weighted Average Diluted Shares Outstanding		 2.95M 2.87M 4.32M 4.75M 5.31M 5.02M 6.34M 8.62M 11.01M 9.27M 11.03M
Weighted Average Basic & Diluted Shares Outstanding		 48.98M 68.34M 70.08M 79.73M 5.70M 6.52M 7.94M 10.38M 11.03M 11.03M 11.03M

Annual Cash Flow Statements for Brainstorm Cell Therapeutics

This table details how cash moves in and out of Brainstorm Cell Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -3.82 0.12 1.94 -1.54 -0.41 37 -19 -18 0.71 -1.11 -0.10
Net Cash From Operating Activities		 -7.41 -5.86 -2.36 -12 -11 -35 -26 -19 -20 -9.09 -6.98
Net Cash From Continuing Operating Activities		 -7.41 -5.86 -2.36 -12 -11 -35 -26 -19 -20 -9.09 -6.98
Net Income / (Loss) Continuing Operations		 -8.49 -4.98 -4.95 -14 -23 -32 -24 -24 -17 -12 -10
Consolidated Net Income / (Loss)		 -8.49 -4.98 -4.95 -14 -23 -32 -24 -24 -17 -12 -10
Depreciation Expense		 0.09 0.08 0.09 0.11 0.16 0.22 0.26 0.29 0.27 0.24 0.20
Non-Cash Adjustments To Reconcile Net Income		 1.15 1.14 0.45 0.78 1.66 4.21 1.65 2.16 -3.36 1.06 1.43
Changes in Operating Assets and Liabilities, net		 -0.16 -2.09 2.05 0.67 10 -7.81 -3.72 2.52 -0.18 1.23 1.70
Net Cash From Investing Activities		 -11 5.98 3.99 -1.22 5.62 -4.45 0.32 1.00 2.19 0.01 0.00
Net Cash From Continuing Investing Activities		 -11 5.98 3.99 -1.22 5.62 -4.45 0.32 1.00 2.19 0.01 0.00
Purchase of Property, Plant & Equipment		 -0.05 -0.10 -0.18 -0.37 -0.47 -0.38 -0.33 -0.03 -0.02 0.01 0.00
Net Cash From Financing Activities		 15 0.00 0.31 12 5.23 77 6.97 0.24 19 7.97 6.88
Net Cash From Continuing Financing Activities		 15 0.00 0.31 12 5.23 77 6.97 0.24 19 7.97 6.88
Issuance of Debt		 - - - - - - - - - 0.00 0.58
Issuance of Common Equity		 12 - - 0.00 2.06 61 6.96 0.24 19 7.97 5.85
Other Financing Activities, net		 2.46 0.00 0.31 12 3.16 16 0.01 - - 0.00 0.45

Quarterly Cash Flow Statements for Brainstorm Cell Therapeutics

This table details how cash moves in and out of Brainstorm Cell Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 7.44 -6.50 -0.52 2.69 -3.30 0.02 1.46 -0.80 -0.79 0.04 -0.07
Net Cash From Operating Activities		 -6.41 -3.29 -3.06 -1.68 -3.30 -1.05 -1.63 -3.50 -1.10 -0.74 -1.32
Net Cash From Continuing Operating Activities		 0.35 -10 -3.06 -1.68 -3.30 -1.05 -1.63 -3.50 -1.10 -0.74 -1.32
Net Income / (Loss) Continuing Operations		 -1.23 -5.58 -3.40 -2.54 -2.71 -2.97 -2.86 -2.90 -2.11 -2.43 -2.13
Consolidated Net Income / (Loss)		 -1.23 -5.58 -3.40 -2.54 -2.71 -2.97 -2.86 -2.90 -2.11 -2.43 -2.13
Depreciation Expense		 0.07 0.07 0.06 0.06 0.06 0.05 0.05 0.05 0.05 0.05 0.04
Non-Cash Adjustments To Reconcile Net Income		 0.84 -4.72 1.23 -0.09 -0.04 -0.05 0.05 0.56 0.36 0.46 0.33
Changes in Operating Assets and Liabilities, net		 0.68 0.18 -0.95 0.88 -0.61 1.92 1.13 -1.21 0.60 1.19 0.44
Net Cash From Investing Activities		 -0.01 0.20 0.00 - - 0.01 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 0.01 0.18 0.00 - - 0.01 0.00 - - - 0.00
Net Cash From Financing Activities		 7.10 3.35 2.54 4.37 - 1.06 3.09 2.70 0.31 0.78 1.25
Net Cash From Continuing Financing Activities		 7.10 3.35 2.54 4.37 - 1.06 3.09 2.70 0.31 0.78 1.25
Issuance of Debt		 - - 0.00 - - - 1.59 -1.10 - 0.78 0.28
Issuance of Common Equity		 16 3.35 2.54 4.37 - 1.06 1.50 3.35 0.31 -0.00 0.97

Annual Balance Sheets for Brainstorm Cell Therapeutics

This table presents Brainstorm Cell Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 17 11 11 11 6.53 51 29 8.45 4.21 1.83 1.02
Total Current Assets		 17 10 9.62 10 3.36 43 23 3.11 1.90 0.39 0.31
Cash & Equivalents		 0.43 0.55 2.48 0.94 0.54 38 19 0.77 1.30 0.19 0.03
Note & Lease Receivable		 0.76 0.31 0.67 2.01 2.36 0.30 0.09 0.09 0.05 0.06 0.09
Prepaid Expenses		 0.07 0.17 1.20 1.20 0.43 1.00 1.10 0.03 0.55 0.14 0.19
Plant, Property, & Equipment, net		 0.27 0.00 0.00 0.00 0.00 1.12 1.19 0.93 0.69 0.43 0.24
Total Noncurrent Assets		 0.02 0.32 1.80 0.96 3.17 6.90 4.81 4.41 1.62 1.01 0.48
Other Noncurrent Operating Assets		 0.02 0.32 1.80 0.96 3.17 6.90 4.81 4.41 1.62 1.01 0.48
Total Liabilities & Shareholders' Equity		 17 11 11 11 6.53 51 29 8.45 4.21 1.83 1.02
Total Liabilities		 2.95 0.86 5.54 6.21 19 16 9.94 11 9.07 9.60 11
Total Current Liabilities		 2.95 0.86 5.54 6.21 18 11 6.32 8.80 7.80 8.98 11
Short-Term Debt		 - - - - - - - - - 0.30 0.97
Accounts Payable		 1.45 0.71 2.10 5.17 15 7.32 4.77 6.22 4.95 6.08 7.07
Accrued Expenses		 1.50 0.15 0.82 1.04 1.00 1.26 0.08 0.08 1.24 0.62 0.40
Current Employee Benefit Liabilities		 - - - - - - - 1.07 1.00 1.43 2.37
Other Current Liabilities		 - - - 0.00 1.26 2.66 1.46 1.43 0.60 0.55 0.21
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 1.10 4.56 3.62 2.67 1.27 0.62 0.00
Total Equity & Noncontrolling Interests		 14 9.90 5.88 5.02 -12 35 19 -3.02 -4.86 -7.76 -9.99
Total Preferred & Common Equity		 14 9.90 5.88 5.02 -12 35 19 -3.02 -4.86 -7.76 -9.99
Total Common Equity		 14 9.90 5.88 5.02 -12 35 19 -3.02 -4.86 -7.76 -9.99
Common Stock		 84 85 86 95 105 185 193 195 210 219 227
Retained Earnings		 -70 -75 -80 -94 -117 -149 -174 -198 -215 -227 -237
Other Equity Adjustments		 - - 0.00 4.41 0.00 - - - - - -0.12

Quarterly Balance Sheets for Brainstorm Cell Therapeutics

This table presents Brainstorm Cell Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 5.68 3.35 5.68 2.03 3.57 2.57 1.38 0.76
Total Current Assets		 1.54 1.26 3.82 0.36 2.33 1.52 0.51 0.18
Cash & Equivalents		 1.22 0.78 3.47 0.17 1.64 0.82 0.01 0.02
Note & Lease Receivable		 0.07 0.03 0.03 0.04 0.07 0.11 0.08 0.12
Prepaid Expenses		 0.06 0.45 0.31 0.16 0.62 0.59 0.42 0.05
Plant, Property, & Equipment, net		 0.75 0.62 0.56 0.50 0.38 0.33 0.28 0.20
Total Noncurrent Assets		 3.39 1.47 1.31 1.16 0.86 0.72 0.59 0.37
Other Noncurrent Operating Assets		 3.39 1.47 1.31 1.16 0.86 0.72 0.59 0.37
Total Liabilities & Shareholders' Equity		 5.68 3.35 5.68 2.03 3.57 2.57 1.38 0.76
Total Liabilities		 8.26 8.90 9.21 8.08 11 8.62 9.07 12
Total Current Liabilities		 6.32 6.83 7.69 7.08 11 8.53 9.02 12
Short-Term Debt		 - - - - 1.20 0.10 0.10 1.33
Accounts Payable		 4.95 4.69 5.34 4.60 6.80 6.00 6.42 7.32
Accrued Expenses		 0.06 0.64 0.72 0.87 0.54 0.37 0.35 0.41
Current Employee Benefit Liabilities		 - 0.92 1.07 1.04 1.92 1.68 1.88 2.55
Other Current Liabilities		 1.31 0.59 0.57 0.57 0.44 0.38 0.28 0.16
Total Noncurrent Liabilities		 1.94 2.07 1.52 1.00 0.13 0.10 0.05 0.00
Total Equity & Noncontrolling Interests		 -2.58 -5.55 -3.53 -6.06 -7.46 226 -7.69 -11
Total Preferred & Common Equity		 -2.58 -5.55 -3.53 -6.06 -7.46 -6.06 -7.69 -11
Total Common Equity		 -2.58 -5.55 -3.53 -6.06 -7.46 226 -7.69 -11
Common Stock		 207 213 218 218 222 226 227 228
Retained Earnings		 -209 -218 -221 -224 -230 0.00 -235 -239
Other Equity Adjustments		 - - - - - - - -0.12

Annual Metrics And Ratios for Brainstorm Cell Therapeutics

This table displays calculated financial ratios and metrics derived from Brainstorm Cell Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 18,498,289.00 18,687,987.00 18,842,726.00 20,707,237.00 22,606,492.00 31,567,592.00 36,277,953.00 36,541,779.00 48,981,588.00 5,703,426.00 11,034,775.00
DEI Adjusted Shares Outstanding		 18,498,289.00 18,687,987.00 18,842,726.00 20,707,237.00 22,606,492.00 31,567,592.00 36,277,953.00 36,541,779.00 48,981,588.00 5,703,426.00 11,034,775.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.46 -0.27 -0.26 -0.67 -1.03 -1.01 -0.67 -0.66 -0.35 -2.04 -0.93
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 7.56% 0.00% 1.84% -183.94% -63.67% -37.78% 22.84% -1.06% 32.84% 31.40% 15.31%
EBIT Growth		 7.68% 0.00% 1.65% -181.32% -63.56% -37.75% 22.55% -1.15% 32.54% 31.05% 15.35%
NOPAT Growth		 7.68% 0.00% 1.65% -181.32% -63.56% -37.75% 22.55% -1.15% 13.63% 45.46% 14.88%
Net Income Growth		 8.20% 0.00% 0.60% -181.66% -66.71% -36.80% 23.12% 0.74% 29.18% 32.39% 11.32%
EPS Growth		 0.00% 0.00% 0.00% 0.00% -51.43% -0.94% 36.45% 2.94% 29.18% 61.50% 51.95%
Operating Cash Flow Growth		 -65.10% 20.92% 59.64% -424.03% 9.21% -212.91% 25.37% 26.44% -5.89% 55.55% 23.29%
Free Cash Flow Firm Growth		 -11.21% 0.00% 0.00% -473.57% 44.62% -432.02% 26.67% 32.39% -5.08% 54.93% 16.75%
Invested Capital Growth		 1.03% 0.00% -2,877.78% -9.17% -524.61% 49.41% 57.48% -117.95% -2.67% -24.24% -18.25%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -68.70% -10.66% -13.79% 17.88% 5.02% 22.56% -21.34% -1.74%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -67.66% -10.73% -13.73% 17.70% 4.97% 22.30% -20.64% -1.65%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -67.66% -10.73% -13.73% 17.70% 4.97% 0.52% 12.14% 8.67%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -68.27% -11.02% -14.89% 18.70% 4.61% 19.82% -13.49% -2.82%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.71% 19.82% 67.65% 22.38%
Operating Cash Flow Q/Q Growth		 8.81% 1.60% -278.24% -6.79% 3.81% -13.92% 7.31% 4.26% 6.25% 19.74% 4.23%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 18.19% -11.43% -0.37% 6.66% 13.24% 5.62% 10.96%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -124.32% -43.63% -128.69% 4.54% 0.50% -53.95% -22.91% -19.09%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.44% 98.01% 99.06% 99.18% 101.10% 100.00% 100.00% 100.00% 102.67% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.40% 99.67% 97.80% 100.00% 100.67% 105.45%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -81.60% -41.46% -62.76% -256.02% 645.29% -273.75% -89.25% -297.38% 436.73% 184.17% 116.14%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -81.60% -41.46% -62.76% -256.02% 645.29% -273.75% -89.25% -297.38% 436.73% 184.17% 116.14%
Return on Equity Simple (ROE_SIMPLE)		 -60.08% -50.31% -84.22% -278.07% 190.24% -89.70% -126.45% 805.21% 353.89% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.98 -3.56 -3.50 -9.84 -16 -22 -17 -17 -15 -8.19 -6.97
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -20.53% -14.29% -16.40% -55.38% -187.40% -45.32% -22.74% -55.04% -102.02% -579.26% 635.57%
Return On Investment Capital (ROIC_SIMPLE)		 -42.29% - - - - - - - 308.92% 109.66% 77.26%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -8.54 -5.08 -5.00 -14 -23 -32 -25 -25 -17 -12 -9.77
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.45 -5.01 -4.91 -14 -23 -31 -24 -25 -16 -11 -9.58
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.74 4.79 12.56 14.66 0.00 4.03 7.50 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 3.74 4.79 12.56 14.66 0.00 4.03 7.50 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.04 -0.10
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.18 -1.01 -1.12 -1.36 1.06 -1.83 -1.17 -1.54 0.54 0.09 -0.06
Leverage Ratio		 1.30 1.16 1.41 2.08 -2.46 2.49 1.47 2.31 -1.61 -0.48 -0.16
Compound Leverage Factor		 1.30 1.16 1.41 2.08 -2.46 2.50 1.46 2.26 -1.61 -0.48 -0.17
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4.02% -10.72%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4.02% -10.72%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 104.02% 110.72%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.03 -0.10
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.10
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.04 -0.14
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.13
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 4.33 22.70 -2.83 -8.32 -36.27 0.06 -1.61 -40.14 -85.46 -198.22 -368.37
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.69 12.09 1.74 1.65 0.19 3.85 3.69 0.35 0.24 0.04 0.03
Quick Ratio		 5.66 11.92 1.52 1.46 0.17 3.76 3.51 0.35 0.17 0.03 0.01
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.99 0.00 -1.69 -9.67 -5.36 -28 -21 -14 -15 -6.69 -5.57
Operating Cash Flow to CapEx		 -16,462.22% -5,687.38% -1,313.33% -3,357.18% -2,377.80% -9,310.32% -7,959.09% -66,620.69% -113,655.56% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -224.40 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -277.11 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -280.09 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.83 -0.06 -1.88 -2.05 -13 -6.47 -2.75 -6.00 -6.16 -7.65 -9.05
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.02 0.00 -1.81 -0.17 -11 6.32 3.72 -3.25 -0.16 -1.49 -1.40
Enterprise Value (EV)		 37 37 66 66 96 101 123 57 12 23 7.04
Market Capitalization		 53 47 74 74 97 143 145 60 13 22 6.10
Book Value per Share		 $0.76 $0.53 $0.31 $0.24 ($0.54) $1.12 $0.53 ($0.08) ($0.10) ($1.36) ($0.90)
Tangible Book Value per Share		 $0.76 $0.53 $0.31 $0.24 ($0.54) $1.12 $0.53 ($0.08) ($0.10) ($1.36) ($0.90)
Total Capital		 14 9.90 5.88 5.02 -12 35 19 -3.02 -4.86 -7.46 -9.02
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.30 0.97
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -16 -9.99 -7.76 -7.06 -0.57 -42 -22 -2.98 -1.30 0.11 0.94
Capital Expenditures (CapEx)		 0.05 0.10 0.18 0.37 0.47 0.38 0.33 0.03 0.02 -0.01 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.12 -0.41 -3.68 -3.01 -15 -9.93 -5.13 -8.68 -7.20 -8.48 -9.76
Debt-free Net Working Capital (DFNWC)		 14 9.58 4.08 4.06 -14 32 17 -5.69 -5.90 -8.29 -9.73
Net Working Capital (NWC)		 14 9.58 4.08 4.06 -14 32 17 -5.69 -5.90 -8.59 -11
Net Nonoperating Expense (NNE)		 2.51 1.42 1.45 4.10 7.15 9.63 7.28 6.90 2.18 3.44 3.34
Net Nonoperating Obligations (NNO)		 -16 -9.97 -7.76 -7.06 -0.57 -42 -22 -2.98 -1.30 0.11 0.94
Total Depreciation and Amortization (D&A)		 0.09 0.08 0.09 0.11 0.16 0.22 0.26 0.29 0.27 0.24 0.20
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($1.06) ($1.07) ($0.68) ($0.66) ($6.00) ($2.31) ($1.11)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 18.66M 19.07M 29.49M 26.23M 35.72M 36.18M 36.51M 2.87M 5.02M 9.27M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($1.06) ($1.07) ($0.68) ($0.66) ($6.00) ($2.31) ($1.11)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 18.66M 19.07M 29.49M 26.23M 35.72M 36.18M 36.51M 2.87M 5.02M 9.27M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($1.06) ($1.07) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 18.66M 18.78M 20.00M 21.91M 29.85M 36.49M 36.68M 4.56M 6.52M 11.03M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.98 -3.56 -3.50 -9.84 -16 -22 -17 -17 -15 -8.19 -6.97
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -249.48 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -174.64 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -252.46 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -177.61 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -0.36% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Brainstorm Cell Therapeutics

This table displays calculated financial ratios and metrics derived from Brainstorm Cell Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 45,015,800.00 48,981,588.00 68,341,857.00 70,080,523.00 5,703,426.00 5,703,426.00 6,522,350.00 7,938,876.00 10,376,109.00 11,034,775.00 11,034,775.00
DEI Adjusted Shares Outstanding		 45,015,800.00 48,981,588.00 68,341,857.00 70,080,523.00 5,703,426.00 5,703,426.00 6,522,350.00 7,938,876.00 10,376,109.00 11,034,775.00 11,034,775.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.03 -0.11 -0.05 -0.04 -0.47 -0.52 -0.44 -0.37 -0.20 -0.22 -0.19
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 11.83% 99.09% 34.11% 38.15% 56.53% -4,518.18% 14.69% 24.24% 22.97% -8.07% 29.71%
EBIT Growth		 11.78% 97.76% 33.72% 37.73% 56.02% -1,795.45% 14.76% 24.17% 22.87% -7.63% 29.69%
NOPAT Growth		 11.78% 2.26% 51.97% 45.27% 49.49% 33.62% -24.86% 13.72% 32.84% 29.63% 33.77%
Net Income Growth		 12.00% 84.68% 32.77% 36.89% 55.13% -179.71% 15.79% 13.68% 22.23% -13.16% 25.73%
EPS Growth		 12.00% 84.68% 32.77% 36.89% -13.33% 76.80% 40.00% 43.33% 62.75% 71.11% 57.78%
Operating Cash Flow Growth		 -32.14% 29.32% 23.16% 75.17% 48.53% 68.10% 46.75% -108.08% 66.60% 29.39% 19.07%
Free Cash Flow Firm Growth		 -280.39% -1,546.68% -450.43% 107.79% 101.46% 76.92% 76.10% -824.01% -166.63% 76.36% 161.29%
Invested Capital Growth		 33.64% -2.67% 10.44% -51.10% -55.63% -24.24% -24.84% 3.09% -22.04% -18.25% -22.71%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -10.93% 99.26% -7,513.64% 0.63% 22.05% 21.70% -40.65% 11.76% 20.74% -9.85% 8.52%
EBIT Q/Q Growth		 -10.75% 98.18% -3,003.64% 0.62% 21.78% 21.44% -39.57% 11.58% 20.44% -9.62% 8.82%
NOPAT Q/Q Growth		 -10.75% 20.40% 48.50% -20.53% -2.21% -4.63% 3.14% 16.70% 20.44% -9.62% 8.82%
Net Income Q/Q Growth		 -13.25% 87.26% -342.26% 1.12% 19.48% 20.57% -33.15% -1.36% 27.45% -15.57% 12.61%
EPS Q/Q Growth		 -13.25% 87.26% -342.26% 1.12% 15.00% 11.76% 0.00% 24.44% 44.12% 31.58% -46.15%
Operating Cash Flow Q/Q Growth		 5.44% 48.74% 6.76% 45.05% -96.02% 68.23% -55.63% -114.71% 68.53% 32.85% -78.38%
Free Cash Flow Firm Q/Q Growth		 -74.78% 48.78% 22.89% 111.28% -67.19% -908.86% 20.15% -241.71% 96.98% -187.03% 306.98%
Invested Capital Q/Q Growth		 13.61% -53.95% -2.78% -10.54% 11.02% -22.91% -3.27% 14.19% -12.05% -19.09% -7.16%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 238.82% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 101.93% 100.00%
Interest Burden Percent		 100.00% 292.73% 99.62% 99.12% 102.03% 103.17% 98.42% 112.83% 102.88% 106.42% 103.96%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 3,591.46% 436.73% 299.02% 366.26% 237.09% 184.17% 170.46% -9.54% 145.80% 116.14% 103.65%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 3,591.46% 436.73% 299.02% 366.26% 237.09% 184.17% 170.46% -9.54% 145.80% 116.14% 103.65%
Return on Equity Simple (ROE_SIMPLE)		 830.40% 0.00% 279.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.22 -3.36 -1.73 -2.09 -2.13 -2.23 -2.16 -1.80 -1.43 -1.57 -1.43
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -40.99% 121.12% -111.06% -60.50% -72.43% 13.70% -114.75% -0.93% -1,869.72% 164.26% 159.72%
Return On Investment Capital (ROIC_SIMPLE)		 - 69.22% 31.20% 59.18% 35.23% 29.91% 34.56% -0.80% 18.87% 17.42% 14.80%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -6.04 -0.11 -3.41 -3.39 -2.65 -2.09 -2.91 -2.57 -2.05 -2.24 -2.05
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.97 -0.04 -3.35 -3.33 -2.60 -2.03 -2.86 -2.52 -2.00 -2.20 -2.01
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 -0.04 -0.16 0.00 -0.01 -0.10 -0.12
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 7.40 0.54 0.29 0.57 0.18 0.09 0.09 -1.06 0.01 -0.06 -0.05
Leverage Ratio		 -15.86 -1.61 -1.08 -1.54 -0.89 -0.48 -0.53 0.04 -0.25 -0.16 -0.23
Compound Leverage Factor		 -15.86 -4.71 -1.08 -1.53 -0.91 -0.49 -0.52 0.04 -0.25 -0.17 -0.24
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% -4.02% -19.18% 0.04% -1.33% -10.72% -13.73%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% -4.02% -19.18% 0.04% -1.33% -10.72% -13.73%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 104.02% 119.18% 99.96% 101.33% 110.72% 113.73%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.03 -0.11 -0.01 -0.01 -0.10 -0.15
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.01 0.04 0.07 -0.01 -0.10 -0.15
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.04 -0.14 -0.01 -0.01 -0.14 -0.21
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.01 0.05 0.09 -0.01 -0.13 -0.21
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -55.46 -72.42 -94.83 -55.68 -139.67 -181.18 -94.15 -5.97 -249.72 -344.06 -470.12
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.24 0.24 0.18 0.50 0.05 0.04 0.21 0.18 0.06 0.03 0.02
Quick Ratio		 0.23 0.17 0.12 0.46 0.03 0.03 0.16 0.11 0.01 0.01 0.01
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.25 -3.20 -2.47 0.28 0.09 -0.74 -0.59 -2.02 -0.06 -0.17 0.36
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -4.00 -6.16 -6.33 -7.00 -6.23 -7.65 -7.90 -6.78 -7.60 -9.05 -9.70
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 2.03 -0.16 0.74 -2.37 -2.23 -1.49 -1.57 0.22 -1.37 -1.40 -1.79
Enterprise Value (EV)		 7.59 12 27 20 313 23 25 8.17 7.44 7.04 12
Market Capitalization		 9.01 13 28 24 313 22 26 8.89 7.34 6.10 10
Book Value per Share		 ($0.06) ($0.10) ($0.11) ($0.05) ($0.08) ($1.36) ($1.31) $28.51 ($0.74) ($0.90) ($1.00)
Tangible Book Value per Share		 ($0.06) ($0.10) ($0.11) ($0.05) ($0.08) ($1.36) ($1.31) $28.51 ($0.74) ($0.90) ($1.00)
Total Capital		 -2.58 -4.86 -5.55 -3.53 -6.06 -7.46 -6.26 226 -7.59 -9.02 -9.68
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.30 1.20 0.10 0.10 0.97 1.33
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1.42 -1.30 -0.78 -3.47 -0.17 0.11 -0.44 -0.72 0.10 0.94 1.31
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.20 -7.20 -6.35 -7.34 -6.89 -8.48 -9.01 -7.74 -8.42 -9.76 -10
Debt-free Net Working Capital (DFNWC)		 -4.78 -5.90 -5.57 -3.88 -6.72 -8.29 -7.37 -6.91 -8.41 -9.73 -10
Net Working Capital (NWC)		 -4.78 -5.90 -5.57 -3.88 -6.72 -8.59 -8.57 -7.01 -8.52 -11 -12
Net Nonoperating Expense (NNE)		 1.81 -2.59 1.67 1.28 0.57 -0.08 0.70 1.10 0.67 0.86 0.69
Net Nonoperating Obligations (NNO)		 -1.42 -1.30 -0.78 -3.47 -0.17 0.11 -0.44 -233 0.10 0.94 1.31
Total Depreciation and Amortization (D&A)		 0.07 0.07 0.06 0.06 0.06 0.05 0.05 0.05 0.05 0.05 0.04
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.45) ($29.10) ($0.75) ($0.60) ($0.51) ($0.45) ($0.45) ($0.34) ($0.19) ($0.13) ($0.19)
Adjusted Weighted Average Basic Shares Outstanding		 2.95M 191.45K 4.32M 4.75M 5.31M 5.02M 6.34M 8.62M 11.01M 9.27M 11.03M
Adjusted Diluted Earnings per Share		 ($0.45) ($29.10) ($0.75) ($0.60) ($0.51) ($0.45) ($0.45) ($0.34) ($0.19) ($0.13) ($0.19)
Adjusted Weighted Average Diluted Shares Outstanding		 2.95M 191.45K 4.32M 4.75M 5.31M 5.02M 6.34M 8.62M 11.01M 9.27M 11.03M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($29.10) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 3.27M 4.56M 4.67M 5.32M 5.70M 6.52M 7.94M 10.38M 11.03M 11.03M 11.03M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.22 -3.36 -1.73 -2.09 -2.13 -2.23 -2.16 -1.80 -1.43 -1.57 -1.43
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Brainstorm Cell Therapeutics (NASDAQ: BCLI) remains a highly cash-dependent, pre-revenue biotech with no meaningful sales and ongoing operating losses. The latest quarter shows some improvement in cash burn versus prior periods, but the company is still funding operations primarily through debt and equity raises while carrying a very weak balance sheet.

  • Q1 2026 operating cash burn improved to -$1.32 million from -$3.50 million in Q2 2025, suggesting better near-term cash discipline.
  • Net loss narrowed to -$2.13 million in Q1 2026 from -$2.43 million in Q4 2025 and -$2.90 million in Q2 2025.
  • Selling, general and administrative expense fell to $1.28 million in Q1 2026 from $1.39 million in Q4 2025.
  • Research and development spending also declined to $762,000 from $852,000 in Q4 2025, which helped reduce the quarterly loss.
  • The company reported no revenue in the latest quarter, so results continue to be driven entirely by operating expenses and financing activity.
  • Net cash from financing activities was $1.25 million in Q1 2026, reflecting continued access to outside funding.
  • Quarter-end cash and equivalents were only $15,000, leaving very limited liquidity on the balance sheet.
  • Total current liabilities remained extremely high at $11.76 million versus total current assets of just $184,000.
  • The company ended Q1 2026 with negative common equity of $11.0 million, a sign of severe balance sheet stress.
  • Accounts payable alone stood at $7.32 million, which is very large relative to the company’s asset base and cash position.

Over the last four years, BCLI has consistently posted losses and negative operating cash flow. There has been a noticeable reduction in quarterly operating expenses since 2023, but that improvement has not been enough to produce profitability or self-funding operations.

The biggest takeaway for retail investors is that liquidity risk remains the central issue. BCLI is still dependent on capital raises, and the balance sheet shows far more liabilities than liquid assets. Until the company generates revenue or materially improves financing stability, the stock will likely remain speculative and highly volatile.

07/26/26 03:41 PM ETAI Generated. May Contain Errors.

Brainstorm Cell Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Brainstorm Cell Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Brainstorm Cell Therapeutics' net income appears to be on an upward trend, with a most recent value of -$10.31 million in 2025, rising from -$8.49 million in 2015. The previous period was -$11.62 million in 2024.

Brainstorm Cell Therapeutics' total operating income in 2025 was -$9.95 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $9.95 million

Over the last 10 years, Brainstorm Cell Therapeutics' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Brainstorm Cell Therapeutics' total liabilities were at $11.01 million at the end of 2025, a 14.7% increase from 2024, and a 272.9% increase since 2015.

In the past 10 years, Brainstorm Cell Therapeutics' cash and equivalents has ranged from $29 thousand in 2025 to $37.83 million in 2020, and is currently $29 thousand as of their latest financial filing in 2025.

Over the last 10 years, Brainstorm Cell Therapeutics' book value per share changed from 0.76 in 2015 to -0.90 in 2025, a change of -218.5%.


Related Companies

Financial statements for NASDAQ:BCLI last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Universal basic income is not impossible. It exist (kind of)
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
BlackRock's $2.8B Clue (most investors missed)
BlackRock's new fund on the emerging financial grid hit 2.8 billion in assets in just three months, according ...
Awesomely | Sponsoredtc pixel
The invention Elon called the greatest in history
Jeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...
Brownstone Research | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel